The effect of race on survival after local therapy in metastatic prostate cancer patients

Authors

  • Elio Mazzone Vita-Salute San Raffaele University
  • Marco Bandini
  • Felix Preisser
  • Sebastiano Nazzani
  • Zhe Tian
  • Firas Abdollah
  • Denis Soulieres
  • Markus Graefen
  • Francesco Montorsi
  • Shahrokh Shariat
  • Fred Saad
  • Alberto Briganti
  • Pierre I. Karakiewicz

DOI:

https://doi.org/10.5489/cuaj.5399

Keywords:

Racial disparities, Metastatic prostate cancer, Local therapy, Radical prostatectomy, Brachytherapy

Abstract

Introduction: Local therapy (LT) may offer a survival advantage in highly select, newly diagnosed metastatic prostate cancer (mPCa) patients. However, it is unknown whether the benefits vary in Caucasian vs. African American (AA) patients.

Methods: Within the Surveillance Epidemiology and End Results (SEER) database (2004–2014), we focused on Caucasians and AA patients with newly diagnosed mPCa treated with LT: radical prostatectomy (RP) and brachytherapy (RT). Endpoints consisted of cancer-specific mortality (CSM) and overall mortality (OM). Kaplan-Meier analyses and multivariable Cox regression models tested for racial difference in CSM and OM.

Results: Between 2004 and 2014, we identified 408 (77.2%) Caucasians and 121 (22.8%) AAs with newly diagnosed mPCa treated with LT: RP (n=357) or RT (n=172). According to race, when LT is defined as RP, Caucasian patients had a significantly longer survival vs. AA patients: CSM-free survival 123 vs. 63 months (p=0.004) and OM-free survival 108 vs. 46 months (p=0.002). The CSM and OM benefits were confirmed in multivariable analyses (hazard ratio [HR] 0.56, p=0.01 for CSM; HR 0.60, p=0.01 for OM). However, no differences in CSM or OM were recorded according to race when LT consisted of RT.

Conclusions: Our results indicate that race is not associated with difference in survival after LT in mPCa patients. However, when focusing on RP-treated patients, Caucasian race is associated with higher CSM and OM rates relative to AA race. This racial difference does not apply to RT. Our findings should be considered in future prospective trials for the purpose of preplanned stratification according to race.

Downloads

Download data is not yet available.

Downloads

Published

2018-10-15

How to Cite

Mazzone, E., Bandini, M., Preisser, F., Nazzani, S., Tian, Z., Abdollah, F., Soulieres, D., Graefen, M., Montorsi, F., Shariat, S., Saad, F., Briganti, A., & Karakiewicz, P. I. (2018). The effect of race on survival after local therapy in metastatic prostate cancer patients. Canadian Urological Association Journal, 13(6). https://doi.org/10.5489/cuaj.5399

Issue

Vol. 13 No. 6 (2019): CUAJ June

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.